Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Phase III Studies

The efficacy of Tygacil in the treatment of skin and soft tissue infections: results of two double-blind phase III comparison studies with vancomycin-aztreonam1

Data obtained from two randomized, double-blind, active-controlled, multi-national, multi-centre studies of 1116 adult patients. Tygacil 100 mg initial dose, followed by 50 mg every 12 hours for up to 14 days. Vancomycin 1g IV every 12 hours + aztreonam 2g IV every 12 hours for up to 14 days1

Tygacil demonstrated efficacy and non-inferiority to vancomycin + aztreonam in cSSTI in adults1

Full preview Percentage of patients who achieved clinical care

Adapted from Ellis-Gross et al. 2005.1

Patients who achieved clinical cure* (%)

*Among clinically evaluable patients at the TOC visit (12–92 days after the last dose); 95% CI for the difference, -6.8% to 2.7% (P<0.001 for non-inferiority).
Cure = resolution of signs and symptoms of infection, or improvement to such an extent that no further antibacterial therapy was necessary.

Cure rates by clinical diagnosis in cSSTI at test of cureβ in clinically evaluable adult patients1

Full preview Cure rates by clinical diagnosis

Adapted from Ellis-Gross et al. 20051

† 12–92 days after the last dose
ǂ Soft tissue infections includes patients with wound infections and cellulitis ≥10 cm requiring surgery/drainage or with complicated pathology

View complicated skin and soft tissue infections (cSSTI) European real-life data

Read more 

References

  1. Ellis-Grosse EJ, Babinchak T, DartoisN, et al. Tigecycline300 and 305 cSSSIStudy Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. ClinInfect Dis.2005;41(suppl5):S341–S353.